U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06859203) titled 'A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PET' on Feb. 27.
Brief Summary: The REFINE study is evaluating whether a fluciclovine (18F) PET/CT scan can detect recurrent prostate cancer in patients whose previous PSMA PET/CT was negative or inconclusive.
Study Start Date: March, 2025
Study Type: OBSERVATIONAL
Condition:
Biochemical Recurrence of Malignant Neoplasm of Prostate
Recruitment Status: RECRUITING
Sponsor: Technical University of Munich
Published by HT Digital Content Services with permission from Health Daily Digest....